Loading…
Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease
Summary Canavan disease is an autosomal recessive leukodystrophy characterized by excessive excretion of N‐acetylaspartic acid (NAA) in urine. The disease is caused by deficiency of aspartoacylase, the enzyme responsible for the hydrolysis of NAA into acetate and l‐aspartate. Patients, who are often...
Saved in:
Published in: | Journal of inherited metabolic disease 2007-08, Vol.30 (4), p.612-612 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3742-80bd229e39a130e32a8ff332fedbb7c85751c9eb32f3889ed4849731ee6e23043 |
---|---|
cites | |
container_end_page | 612 |
container_issue | 4 |
container_start_page | 612 |
container_title | Journal of inherited metabolic disease |
container_volume | 30 |
creator | Al‐Dirbashi, O. Y. Rashed, M. S. Al‐Qahtani, K Al‐Mokhadab, M. A. Kurdi, W. Al‐Sayed, M. A. A. |
description | Summary
Canavan disease is an autosomal recessive leukodystrophy characterized by excessive excretion of N‐acetylaspartic acid (NAA) in urine. The disease is caused by deficiency of aspartoacylase, the enzyme responsible for the hydrolysis of NAA into acetate and l‐aspartate. Patients, who are often asymptomatic in their early months, show a wide spectrum of clinical presentation thereafter that includes macrocephaly, poor head control, seizures, abnormal muscle tone, optic atrophy, significant developmental delay and death. In this work, we describe a simple liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method for the determination of NAA in urine. The internal standard d3‐NAA was added to untreated urine and the mixture was injected into the LC‐MS/MS system operated in the negative ion mode. Detection was achieved in multiple reaction monitoring (MRM) mode by monitoring m/z 174 → 88, 174 → 130 and 174 → 58 for NAA and 177 → 89 for the internal standard. Separation was carried out on a C8 column (2.1 × 150 mm) using a mixture of acetonitrile and water (1:1 v/v) containing 0.05% formic acid at a flow rate of 0.25 ml/min. NAA was eluted at 1.6 min and the run time was approximately 2 min. Using spiked urine, the assay was linear up to 2 mmol/L with limit of quantification at 1 μmol/L (S/N = 12). NAA in patients’ urine (n = 17) ranged between 366 and 21235 mmol/mol creatinine compared to controls of |
doi_str_mv | 10.1007/s10545-007-0635-6 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68239626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1334499741</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3742-80bd229e39a130e32a8ff332fedbb7c85751c9eb32f3889ed4849731ee6e23043</originalsourceid><addsrcrecordid>eNqFkc1u1DAQxy1ERZfCA3BBFgduobYn_jqi5avVLggVzpbjTMBV1lnsBLQ3HoFn5ElItCtV4tLTjEa_-Wk0f0KecfaKM6YvC2eyltXcVkyBrNQDsuJSQyWUkg_JivGaV8ZKeU4el3LLGLNGykfknGsFQlm-Ivh58mmMXQx-jEOiQ0c__v39xwccD70ve5_HGKgPsaUx0SnHhLQ50M16hrY3l9sb2g2Zjt-RttF_S0OJZXGsffI_fZqHBX3BJ-Ss833Bp6d6Qb6-e_tl_aHafHp_tX69qQLoWlSGNa0QFsF6DgxBeNN1AKLDtml0MFJLHiw28wSMsdjWprYaOKJCAayGC_Ly6N3n4ceEZXS7WAL2vU84TMUpI8AqoWbwxX_g7TDlNN_mBDemNgB6hvgRCnkoJWPn9jnufD44ztwSgDsG4JZ2CcAt4ucn8dTssL3bOH18BvQR-BV7PNxvdNdX2zdMcQH_AHPWkcM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218848337</pqid></control><display><type>article</type><title>Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease</title><source>Wiley</source><source>Alma/SFX Local Collection</source><creator>Al‐Dirbashi, O. Y. ; Rashed, M. S. ; Al‐Qahtani, K ; Al‐Mokhadab, M. A. ; Kurdi, W. ; Al‐Sayed, M. A. A.</creator><creatorcontrib>Al‐Dirbashi, O. Y. ; Rashed, M. S. ; Al‐Qahtani, K ; Al‐Mokhadab, M. A. ; Kurdi, W. ; Al‐Sayed, M. A. A.</creatorcontrib><description>Summary
Canavan disease is an autosomal recessive leukodystrophy characterized by excessive excretion of N‐acetylaspartic acid (NAA) in urine. The disease is caused by deficiency of aspartoacylase, the enzyme responsible for the hydrolysis of NAA into acetate and l‐aspartate. Patients, who are often asymptomatic in their early months, show a wide spectrum of clinical presentation thereafter that includes macrocephaly, poor head control, seizures, abnormal muscle tone, optic atrophy, significant developmental delay and death. In this work, we describe a simple liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method for the determination of NAA in urine. The internal standard d3‐NAA was added to untreated urine and the mixture was injected into the LC‐MS/MS system operated in the negative ion mode. Detection was achieved in multiple reaction monitoring (MRM) mode by monitoring m/z 174 → 88, 174 → 130 and 174 → 58 for NAA and 177 → 89 for the internal standard. Separation was carried out on a C8 column (2.1 × 150 mm) using a mixture of acetonitrile and water (1:1 v/v) containing 0.05% formic acid at a flow rate of 0.25 ml/min. NAA was eluted at 1.6 min and the run time was approximately 2 min. Using spiked urine, the assay was linear up to 2 mmol/L with limit of quantification at 1 μmol/L (S/N = 12). NAA in patients’ urine (n = 17) ranged between 366 and 21235 mmol/mol creatinine compared to controls of <39 mmol/mol creatinine (n = 159). This LC‐MS/MS method for NAA as described involved no extraction and no derivatization, showed no interference, and gave excellent recovery with low variability and short analytical time.</description><identifier>ISSN: 0141-8955</identifier><identifier>EISSN: 1573-2665</identifier><identifier>DOI: 10.1007/s10545-007-0635-6</identifier><identifier>PMID: 17632691</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Aspartic Acid - analogs & derivatives ; Aspartic Acid - urine ; Canavan Disease - blood ; Canavan Disease - diagnosis ; Child ; Child, Preschool ; Chromatography, Liquid - methods ; Female ; Humans ; Hydrolysis ; Infant ; Infant, Newborn ; Male ; Mass Spectrometry - methods ; Models, Chemical ; Reference Values ; Urinalysis - methods</subject><ispartof>Journal of inherited metabolic disease, 2007-08, Vol.30 (4), p.612-612</ispartof><rights>2007 SSIEM</rights><rights>SSIEM and Springer 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3742-80bd229e39a130e32a8ff332fedbb7c85751c9eb32f3889ed4849731ee6e23043</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17632691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al‐Dirbashi, O. Y.</creatorcontrib><creatorcontrib>Rashed, M. S.</creatorcontrib><creatorcontrib>Al‐Qahtani, K</creatorcontrib><creatorcontrib>Al‐Mokhadab, M. A.</creatorcontrib><creatorcontrib>Kurdi, W.</creatorcontrib><creatorcontrib>Al‐Sayed, M. A. A.</creatorcontrib><title>Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease</title><title>Journal of inherited metabolic disease</title><addtitle>J Inherit Metab Dis</addtitle><description>Summary
Canavan disease is an autosomal recessive leukodystrophy characterized by excessive excretion of N‐acetylaspartic acid (NAA) in urine. The disease is caused by deficiency of aspartoacylase, the enzyme responsible for the hydrolysis of NAA into acetate and l‐aspartate. Patients, who are often asymptomatic in their early months, show a wide spectrum of clinical presentation thereafter that includes macrocephaly, poor head control, seizures, abnormal muscle tone, optic atrophy, significant developmental delay and death. In this work, we describe a simple liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method for the determination of NAA in urine. The internal standard d3‐NAA was added to untreated urine and the mixture was injected into the LC‐MS/MS system operated in the negative ion mode. Detection was achieved in multiple reaction monitoring (MRM) mode by monitoring m/z 174 → 88, 174 → 130 and 174 → 58 for NAA and 177 → 89 for the internal standard. Separation was carried out on a C8 column (2.1 × 150 mm) using a mixture of acetonitrile and water (1:1 v/v) containing 0.05% formic acid at a flow rate of 0.25 ml/min. NAA was eluted at 1.6 min and the run time was approximately 2 min. Using spiked urine, the assay was linear up to 2 mmol/L with limit of quantification at 1 μmol/L (S/N = 12). NAA in patients’ urine (n = 17) ranged between 366 and 21235 mmol/mol creatinine compared to controls of <39 mmol/mol creatinine (n = 159). This LC‐MS/MS method for NAA as described involved no extraction and no derivatization, showed no interference, and gave excellent recovery with low variability and short analytical time.</description><subject>Aspartic Acid - analogs & derivatives</subject><subject>Aspartic Acid - urine</subject><subject>Canavan Disease - blood</subject><subject>Canavan Disease - diagnosis</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Chromatography, Liquid - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrolysis</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Mass Spectrometry - methods</subject><subject>Models, Chemical</subject><subject>Reference Values</subject><subject>Urinalysis - methods</subject><issn>0141-8955</issn><issn>1573-2665</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqFkc1u1DAQxy1ERZfCA3BBFgduobYn_jqi5avVLggVzpbjTMBV1lnsBLQ3HoFn5ElItCtV4tLTjEa_-Wk0f0KecfaKM6YvC2eyltXcVkyBrNQDsuJSQyWUkg_JivGaV8ZKeU4el3LLGLNGykfknGsFQlm-Ivh58mmMXQx-jEOiQ0c__v39xwccD70ve5_HGKgPsaUx0SnHhLQ50M16hrY3l9sb2g2Zjt-RttF_S0OJZXGsffI_fZqHBX3BJ-Ss833Bp6d6Qb6-e_tl_aHafHp_tX69qQLoWlSGNa0QFsF6DgxBeNN1AKLDtml0MFJLHiw28wSMsdjWprYaOKJCAayGC_Ly6N3n4ceEZXS7WAL2vU84TMUpI8AqoWbwxX_g7TDlNN_mBDemNgB6hvgRCnkoJWPn9jnufD44ztwSgDsG4JZ2CcAt4ucn8dTssL3bOH18BvQR-BV7PNxvdNdX2zdMcQH_AHPWkcM</recordid><startdate>200708</startdate><enddate>200708</enddate><creator>Al‐Dirbashi, O. Y.</creator><creator>Rashed, M. S.</creator><creator>Al‐Qahtani, K</creator><creator>Al‐Mokhadab, M. A.</creator><creator>Kurdi, W.</creator><creator>Al‐Sayed, M. A. A.</creator><general>Springer Netherlands</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200708</creationdate><title>Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease</title><author>Al‐Dirbashi, O. Y. ; Rashed, M. S. ; Al‐Qahtani, K ; Al‐Mokhadab, M. A. ; Kurdi, W. ; Al‐Sayed, M. A. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3742-80bd229e39a130e32a8ff332fedbb7c85751c9eb32f3889ed4849731ee6e23043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aspartic Acid - analogs & derivatives</topic><topic>Aspartic Acid - urine</topic><topic>Canavan Disease - blood</topic><topic>Canavan Disease - diagnosis</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Chromatography, Liquid - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrolysis</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Mass Spectrometry - methods</topic><topic>Models, Chemical</topic><topic>Reference Values</topic><topic>Urinalysis - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al‐Dirbashi, O. Y.</creatorcontrib><creatorcontrib>Rashed, M. S.</creatorcontrib><creatorcontrib>Al‐Qahtani, K</creatorcontrib><creatorcontrib>Al‐Mokhadab, M. A.</creatorcontrib><creatorcontrib>Kurdi, W.</creatorcontrib><creatorcontrib>Al‐Sayed, M. A. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of inherited metabolic disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al‐Dirbashi, O. Y.</au><au>Rashed, M. S.</au><au>Al‐Qahtani, K</au><au>Al‐Mokhadab, M. A.</au><au>Kurdi, W.</au><au>Al‐Sayed, M. A. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease</atitle><jtitle>Journal of inherited metabolic disease</jtitle><addtitle>J Inherit Metab Dis</addtitle><date>2007-08</date><risdate>2007</risdate><volume>30</volume><issue>4</issue><spage>612</spage><epage>612</epage><pages>612-612</pages><issn>0141-8955</issn><eissn>1573-2665</eissn><abstract>Summary
Canavan disease is an autosomal recessive leukodystrophy characterized by excessive excretion of N‐acetylaspartic acid (NAA) in urine. The disease is caused by deficiency of aspartoacylase, the enzyme responsible for the hydrolysis of NAA into acetate and l‐aspartate. Patients, who are often asymptomatic in their early months, show a wide spectrum of clinical presentation thereafter that includes macrocephaly, poor head control, seizures, abnormal muscle tone, optic atrophy, significant developmental delay and death. In this work, we describe a simple liquid chromatography–tandem mass spectrometry (LC‐MS/MS) method for the determination of NAA in urine. The internal standard d3‐NAA was added to untreated urine and the mixture was injected into the LC‐MS/MS system operated in the negative ion mode. Detection was achieved in multiple reaction monitoring (MRM) mode by monitoring m/z 174 → 88, 174 → 130 and 174 → 58 for NAA and 177 → 89 for the internal standard. Separation was carried out on a C8 column (2.1 × 150 mm) using a mixture of acetonitrile and water (1:1 v/v) containing 0.05% formic acid at a flow rate of 0.25 ml/min. NAA was eluted at 1.6 min and the run time was approximately 2 min. Using spiked urine, the assay was linear up to 2 mmol/L with limit of quantification at 1 μmol/L (S/N = 12). NAA in patients’ urine (n = 17) ranged between 366 and 21235 mmol/mol creatinine compared to controls of <39 mmol/mol creatinine (n = 159). This LC‐MS/MS method for NAA as described involved no extraction and no derivatization, showed no interference, and gave excellent recovery with low variability and short analytical time.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>17632691</pmid><doi>10.1007/s10545-007-0635-6</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0141-8955 |
ispartof | Journal of inherited metabolic disease, 2007-08, Vol.30 (4), p.612-612 |
issn | 0141-8955 1573-2665 |
language | eng |
recordid | cdi_proquest_miscellaneous_68239626 |
source | Wiley; Alma/SFX Local Collection |
subjects | Aspartic Acid - analogs & derivatives Aspartic Acid - urine Canavan Disease - blood Canavan Disease - diagnosis Child Child, Preschool Chromatography, Liquid - methods Female Humans Hydrolysis Infant Infant, Newborn Male Mass Spectrometry - methods Models, Chemical Reference Values Urinalysis - methods |
title | Quantification of N‐acetylaspartic acid in urine by LC‐MS/MS for the diagnosis of Canavan disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A01%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantification%20of%20N%E2%80%90acetylaspartic%20acid%20in%20urine%20by%20LC%E2%80%90MS/MS%20for%20the%20diagnosis%20of%20Canavan%20disease&rft.jtitle=Journal%20of%20inherited%20metabolic%20disease&rft.au=Al%E2%80%90Dirbashi,%20O.%20Y.&rft.date=2007-08&rft.volume=30&rft.issue=4&rft.spage=612&rft.epage=612&rft.pages=612-612&rft.issn=0141-8955&rft.eissn=1573-2665&rft_id=info:doi/10.1007/s10545-007-0635-6&rft_dat=%3Cproquest_cross%3E1334499741%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3742-80bd229e39a130e32a8ff332fedbb7c85751c9eb32f3889ed4849731ee6e23043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218848337&rft_id=info:pmid/17632691&rfr_iscdi=true |